EPISODE · May 2, 2025 · 12 MIN
VERAXA Biotech, which is part of Switzerland's Xlife Sciences incubator, will be going public in the U.S. via a SPAC in Q4 of this year. The company uses an AND-gating technology for TCEs and ADCs.
from BiotechTV - News · host BiotechTV
Xlife Sciences CEO Oliver Baumann introduces us to the fund, which is publicly traded in Switzerland, while VERAXA CEO Christoph Antz describes the BiTAC AND-gating platform the company uses to improve on the precision of T-cell engagers and antibody-drug conjugates.
Embed this episode
Ready to play
VERAXA Biotech, which is part of Switzerland's Xlife Sciences incubator, will be going public in the U.S. via a SPAC in Q4 of this year. The company uses an AND-gating technology for TCEs and ADCs.
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.